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Abstract—The analysis of biological markers (biomarkers)
have the ability to improve clinical outcomes of a disease through
prediction and early detection. The constant improvement of
next generation sequencing (NGS) technologies coupled with
falling equipment price are driving research and application
especially in the medical domain. NGS technology is being
applied to cancer research promising greater understanding of
carcinogenesis. However, as sequence capacity grows, algorithmic
speed is becoming an important bottleneck. To understand these
challenges we present a review on difficulties currently faced
in discovering biomarkers. The review places the spotlight on
sequencing technologies and the bottlenecks encountered in these
pipelines. Cloud computing and high performance computing
technologies such as Grid are summarized in tackling computa-
tional challenges presented by technologies and algorithms used
in biomarker research.
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I. INTRODUCTION
Biological markers (biomarkers) are defined by the National
Institute of Heath as: “A characteristic that is objectively
measured and evaluated as an indicator of normal biologic
processes, pathogenic processes or pharmacologic responses
to a therapeutic intervention”. In practice, biomarkers include
tools and technologies that can aid in our understanding of
the cause, diagnosis, progression, outcome of treatment and
prediction of disease [1].
Biomarkers in medicine could be a measurement or obser-
vation of an identified biological process which is used to
indicate the presence of a specific disease [2]. For example,
a protein, tissue, group of cells or fluids found in a human
biopsy sample may be predictive or prognostic of a particular
disease. A list of differentially expressed gene when clustered
could stratify patients by prognosis or response to treatment
[3]. Analysis from clinical data can be used to determine gene
signatures with appropriate thresholds that can be used in the
development of clinical tests, used for example, in treatment
guidance.
A wide range of biomarkers exists including: biochemical
and immunological molecular markers through to metabolites
or processes such as apoptosis, angiogenesis and proliferation
[2]. Biomarkers can be detected in plasma, serum, cerebral
spinal fluid, urine, saliva and cyst fluids. Examples of disease
biomarkers include: the diagnosis of diabetes based on the
level of glucose in serum after 12 hours of fasting. The
most sensitive indicator of a cardio-vascular event (including
myocardial infarction) is an elevated level of cardiac troponin
in serum [2]. The level of serum creatinine is the single most
important indicator of renal function. The recent revolutionary
advancements in molecular diagnostics and high-throughput
DNA sequencing will likely provide many new biomarkers
(including gene mutations, copy number variations, and/or
single nucleotide polymorphisms) for predisposition to various
diseases and prediction of therapeutic response to a treatment
or its toxicity.
Biomarkers have improved identification, treatment and
prevention of complex common diseases including cancer,
diabetes and cardiovascular disease [4]. Moreover, they have
been applied to identify diseases such as alzheimer’s [5], breast
cancer [6] and kidney disease [7] playing a central role in
the identification of novel targeted and effective therapeutics.
However, the current clinical implications of basic and trans-
lational research efforts are modest.
Much progress has been made in the development of
high-throughput experimental and technical approaches which
have been applied to identify and quantitatively measure
biomarkers. The availability of cDNA, oligonucleotide
microarrays [8] and Next Generation Sequencing (NGS)
such as mRNA-Seq [9] which assesses the global transcript
profiles from tissue and cell samples of clinical interest.
Other techniques include mass spectrometry-based laser-
capture microdissection [10] which are providing functional
characteristics and size of protein extracts. These technologies
are capable of producing vasts amount of biological data
requiring the development and application of computational
and statistical approaches to analyze and interpret the
results. The reduction in cost of sequencing has been
instrumental in prominent research projects such as the
1,000 Genomes project [11], whereby human genomes
are sequenced and genetic variation cataloged. The sheer
volume of data produced by these projects necessitates
high performance and scalability computing solutions. For
example, it has been estimated that raw data generated
by the 1,000 genome project during the first six months
of the project deposited in the NCBIs GenBank is two
times more than all previous sequence deposits in the
last 30 years [12]. Furthermore, research in areas such as
cancer and microbiology including projects such as The
Cancer Genome Atlas [13] are undertaking sequencing in
the order of magnitude larger than the 1,000 Genomes project.
In this review we will provide an overview on the current
challenges faced in biomarker discover. We will focus on the
technologies such as sequencing technologies, the bottlenecks
encountered and the applications exploiting Cloud and high
performance computing to improve power and speed, owing
to the computational challenges presented by many of the tech-
nologies and algorithms that are used in biomarker research.
Finally, we conclude on future challenges in this field.
II. CHALLENGES IN BIOMARKER DEVELOPMENT
The past 20 years has seen major investments with the
aim of discovering and validating cancer biomarkers. Three
successful multi-gene signatures that have been incorporated
into current clinical practice are MammaPrint [14], Oncotype
DX [15] and Prosigma PAM50 [16] and have had a positive
impact. However, no new major cancer biomarkers have been
approved for clinical use for at least 25 years [2]. Furthermore,
only 0.07% of published biomarkers have made their way into
routine clinical use with very few biomarkers useful for cancer
diagnosis and monitoring. [17].
A major challenge in biomarker discovery is due to the
complexity in detecting and validating associations within
large heterogeneous datasets. This is further complicated due
to the lack of resources and multidisciplinary expertise within
small academic teams. Validating potential biomarkers is yet
another major obstacle. This has been recognized by the US
Food and Drug Administration (FDA) who have established
a Biomarker Qualification Program to support the Center for
Drug Evaluation and Research work with external scientists
and clinicians in developing biomarkers.
Some of the biomarker development limitations result from
data issues resulting from tissue collection, non-standard pro-
tocols, technical/batch effects, bias, power, and lack of vali-
dation. Standardized approaches are needed to help eliminate
variations in practice. This is of particular importance due to
the vast amount of data sets generated as a result of testing
multiple biomarkers. Development in standardized approaches
is ongoing. For example the Cancer Institute’s Cancer Human
Biobank (caHUB) [18] has established stringent guidelines
on collection, annotation, storage, and analysis of samples.
In terms of algorithmic development there are further issues
regarding inappropriate tests, lack of repeatability and general
robustness.
Poste [17] suggests larger scale collaborative multidisci-
plinary teams bringing together industry, clinical practice and
scientific research are necessary for biomarker development to
reach its full potential. Yang et al. [19] highlight some of the
challenges associated with developing prognostic indicators
for breast cancer. Integration of information such as gene
deletions, translocations, and locus amplification; biomarkers
from high-throughput -omics technologies such as genomics,
proteomics, and metabolomics; and long recognized outcome
variables such as tumor size, histologic grade, axillary nodal
status, and estrogen receptor (ER) status [19] can be used to
provide a more tailored therapy. One of the key challenges
is the integration of -omics data to provide a robust and
effective solution. There is however current research interest
in combining new NGS technologies with existing microarray
technologies to enable a combining of multiple complementary
resources.
III. TECHNOLOGY APPLIED TO IDENTIFY AND VALIDATE
BIOMARKERS
With the challenge issued by the FDAs Critical Path Initia-
tive to make better use of genomic technologies, biomarkers
are set to have an ever more important role in the drug de-
velopment process. In the past decade, the use of nucleic acid
sequencing has increased as the ability to sequence has become
accessible to research and clinical labs all over the world. The
demand for faster and more economical sequencing has led
to the development of NGS. These technologies have allowed
researchers to characterize the molecular landscape of diverse
cancer types and led to dramatic advances in cancer genomic
studies. NGS could have a central role in the discovery of new
genomic biomarkers, owing to the many different types of ex-
periment that can be performed on a single machine. Further-
more, researchers use a variety of high-throughput technolo-
gies, including transcriptomics using microarrays, genome-
wide association studies (GWAS), metabolomics modeling,
Yeast 2 Hybrid (Y2H) assays, proteomics, high-throughput
chemistry screening and in-silico techniques. NGS is one
piece in the Bioinformatics puzzle and has the potential
to augment or complement these existing technologies. The
key computational challenges will be around developing data
analysis tools that could simultaneously analyse across these
vast data sets, looking for biomarker signatures [20].
A. Common Applications for Next Generation Sequencing
Virtually all areas of biological sciences now use sequenc-
ing. For example, the application of NGS has provided in-
formation on the complexity of cancer genomic alterations
[20]. The comparison of these alterations to matched normal
samples have enabled researchers to distinguish between two
categories of variants: somatic and germ line [21]. There are a
number of experimental processes in which NGS technologies
can be applied. These include:
1) Variant detection: application to find genetic differences
between the studied sample and the reference. These
differences range from single nucleotide variants
(SNVs) to large genomic deletions, insertions, or
rearrangements.
2) RNA-seq: can be used to determine the expression
level of annotated genes as well as to discover novel
transcripts. Furthermore, it can detect alternative
splicing, RNA editing and fusion transcripts.
3) ChIP-seq: is a method for genome-wide screening pro-
teinDNA interactions. They can be used to measure
DNA methylation change and histone modifications.
The combination of NGS technologies provides a high-
resolution and global view of the cancer genome. Using power-
ful bioinformatics tools, researchers aim to decipher the huge
amount of data generated to improve our understanding of
cancer biology and to develop personalized treatment strategy.
IV. COMPUTATIONAL BOTTLENECKS IN BIOMARKER
DISCOVERY
Genome sequencing is continuing to decrease in cost at a
faster rate than the cost of storage [12]. The amount of data
produced by NGS for example are in the orders of magnitude
greater than that generated by earlier techniques such as
Sanger. Analysis algorithms must therefore be optimized for
speed and memory usage. Bottlenecks are observed across
many tasks in the genomic processing pipeline from sample
preparation through to the analysis of the data output from
NGS platforms. A summary of these tasks are presented below.
A. Genomic Sequence Mapping
Reads produced by NGS technologies are relatively short
in length and their throughput several magnitudes higher than
traditional microarray technologies [22]. To use these reads
for tasks such as transcriptome sequencing and gene structure
identification the sequence reads must be aligned over intron
boundaries [23]. When a reference genome assembly exists,
alignment is performed. Taking the read, the alignment process
determines the most likely source of the sequence within the
specific species genome. Developed alignment algorithms are
summarised in Table 1. These methods differ in terms of their
ability to handle reads of different lengths, accuracy in map-
ping “noisy” reads, sensitivity and computational efficiency.
TABLE I
AN OVERVIEW OF KEY SEQUENCE MAPPING ALGORITHMS
Algorithm Description Reference
MAQ Applied in human whole-genome align-
ments. Handles short reads and supports
SNP calling on a diploid sample.
[24]
BWA Integrates the BurrowsWheeler Transform
algorithm with backward search to
align short reads against a reference
genome.Ability to handle gaps and
mismatches.
[25]
BFAST Creates whole genome indexes to map
reads. Use of Smith-Waterman method sup-
porting detection of small indel
[26]
SOAP3 Uses multi-processors in a graphic process-
ing unit (GPU) along with an adapted BWA
algorithm to map reads
[27]
For organisms without a sequenced reference genome, as-
sembly algorithms can be applied for analysis. To assemble
new genomes, benchmark assembled reference genomes in
other species are used. These include “de novo assembly
algorithms” which are based on graph theory such as the de
Bruijn graph formulation [28].
Fig. 1. A summary of tasks in the RNA-Seq analysis pipeline
B. Genomic Sequencing Analysis
Analysis of the sequence data can include a variety of
assessments such as genetic variant calling to detect SNPs,
transcript expression level measurement through to identifi-
cation of novel genes or regulatory elements. As outlined in
Grada et al. [29] analysis can also include the identification
of somatic and germline mutation events which may aid in
the diagnosis of disease. A number of open source software
solutions exist to perform these analysis including GATK [30],
Samtools [31]. These platforms differing in terms of statistical
approaches and sequencing depths.
C. RNA-Seq Analysis
RNA-Seq [32] technologies are providing transcriptome
profiling using deep-sequencing technologies. As described by
Metzher et al. [33] RNA-Seq are advantageous in identifying
and quantifying rare transcripts where no prior knowledge of a
gene exists. Furthermore, for identified genes, they can provide
information on alternative splicing. Fig. 1 provides a summary
of key tasks undertaken in RNA-Seq analysis.
V. CPU & GPU-BASED ACCELERATED COMPUTATIONS
FOR BIOMARKER DISCOVERY
Moores law defined by Intel co-founder Gordon Moore
states ‘’the number of transistors that can be placed on an
integrated circuit board is increasing exponentially, with a dou-
bling time of roughly 18 months” [34]. This law is currently
being outpaced by generation of sequence data and the storage
and processing power required to analyse them. In order to
handle these large data, technological solutions are required to
speed up the analysis of biological data. Technical solutions
differ in terms of cost of resources and technical expertise
required to implement them. Many research institutions may
have limited budget for computational power. There are also
concerns in respect of the data privacy and security, especially,
when the external resources (such as public cloud services) are
used as the data may contain personal information [35]. Hence,
the technologies are discussed in this section, considering their
financial and technical accessibility and security.
A. Commodity Clusters
Over the past decade, large-scale distributed systems of
computing units have become a powerful resource to process
large biological data in parallel. Commodity clusters have
received significant attention in bioinformatics, because of
their low-budget elements and scalability in respect of the
user’s requirements [36], [37]. Commodity clusters consist of
regular computers (servers), connected through the network,
compared to a supercomputer containing many processors.
Parallel execution of tasks on distributed resources is an active
area of research with one of the most famous standards:
Message Passing Interface (MPI) [38]. MPI requires the users
to specify explicitly parallelism in their algorithms, using MPI
functions.
B. Apache Hadoop
The Apache Hadoop project [39] proposes an open-source
software for distributed processing of the large-scale data on
commodity computers. A comprehensive review of Hadoop-
based software and its bioinformatics applications are dis-
cussed in the paper [40]. Apache Hadoop software focuses on
the effective storage and processing of tasks, using the Hadoop
Distributed File System (HDFS) [41] and MapReduce par-
allel programming framework [42] respectively. MapReduce
programming framework consists of several stages. First, the
input data is filtered and presented as a list of intermediate
key and value pairs at the mapping stage. Then, the values
with the same key are grouped together and such groups of
values are sorted by their keys. Finally, the values for each
key are merged together at the reducing stage. MapReduce
programming framework has been widely used and extended
in many parallel solutions, for example, the execution engine
from Microsoft, Dryad [43]; the read mapping algorithm
for the NGS data, CloudBurst [44]; the parallelised BLAST
algorithm for a sequence alignment [45]. There are libraries
that implement MapReduce with MPI such as MR-MPI by
Plimpton and Devine [46].
C. Cloud
Clouds have been widely used in bioinformatics [47], [48],
[49], [50], some of which have already been mentioned above.
Cloud computing provides resources, data storage and process-
ing as a service on a “pay as you go” basis, using a Service
Level Agreement (SLA) [51] protocol. The providers of cloud
services include but are not limited to Amazon, Microsoft and
Google. Clouds allow users to not only use CPU capacity of
their resources, but some also offer Graphics Processor Unit
(GPU) acceleration. An example of this is the Amazon Elastic
Compute Cloud (EC2) instance type, G2, [52].
D. Graphics Processor Unit
Melonakos [53] stated that GPU computing is a promising
approach to biological data analysis, compared to a tradi-
tional parallel computing on CPUs for several reasons. First,
the price to performance ratio is more favourable for GPU
than CPU which was also earlier pointed out by Fan et al.
[54]. Secondly, a GPU was originally designed to process
data in parallel as compared to CPU, which processes data
sequentially [53]. Hence, a GPU card can have thousands of
GPU cores, which can process data in parallel, while more
affordable workstations or servers usually have tens of CPU
cores. The prices on commodity GPUs are also driven down by
the large gaming industry [54]. One of the most popular GPU
cards are produced by NVIDIA [55], and NVIDIA also offers
a platform and model for parallel programming on GPUs, i.e.
Compute Unified Device Architecture (CUDA) [56].
Potentially, GPU computing has promising prospects for
bioinformaticians as it would reduce the cost of hardware,
combining with a significant speed up in calculations. How-
ever, there is a bottleneck for GPU computing, concerned
with developing tools and software, which can be easily
utilised by researchers and developers [53]. Another concern
in respect of GPU computing constitutes a possibly slow data
exchange between GPU and CPU (especially, from GPU to
CPU memory) [57]. Hence, the data exchange time between
those memories might diminish any time surplus resulted from
GPU acceleration. In the recent years, bioinformatics has paid
a substantial attention to the GPU-based computations, and
some of these examples include a GPU-accelerated alignment
of DNA sequences [58], [59]; the statistical computations in R
[60], which is widely used by biologists and bioinformaticians,
such as permGPU package [61]; a molecular dynamics simu-
lation for health research, using the Grid computing paradigm
[62] and GPU computing, GPUGRID [63].
VI. CONCLUSION
The scope and use of omic technologies is vast. Key
areas include biomarker and drug discovery, diagnostics and
personal genomics.
The advent of NGS technologies has resulted in the gen-
eration of biological data at a scale which is outpacing
processing power and storage. Researchers need to reconsider
traditional approaches to data analysis which typically involve
the download of large data sets from resources such as
the European Bioinformatics Institute EMBL database [64]
onto locally maintained storage servers. Instead, technological
solutions are required to address the computationally intensive
processing pipelines. This is not a trivial task. Cloud and
high performance computing although extremely powerful
requires high levels of technical expertise. Bioinformatics
applications are often open source and may be dependent on
other programming libraries. Furthermore, documentation may
be sparse resulting in difficulty in building, configuring and
maintaining applications requiring technical expertise [65].
Algorithms developed will require attention in terms of speed.
For example, read mapping with high accuracy will take
longer to run than a procedure applying heuristics to limit
errors and sequence polymorphism. New data types such
as the interrupted read sequences from complete genomics
will challenge the existing alignment algorithms, as will the
increase in read length and experimental studies that focus
on cancer genomes with multiple deletions, duplications and
rearrangements.
Future application of biomarkers in the clinical setting
will be advantageous in terms of disease prediction and
outcome. New sequencing technologies promise to unravel
complex cancer genomes quickly and at low cost resulting
in massive amounts of data [66]. This clinical pipeline will
require integration of diverse data into the patient pathway,
and guide preventative and therapeutic options, both for di-
agnosis and personalized treatments. Current challenges will
need addressed such as identifying clinically relevant genomic
variation across the whole-human genome; potential error
in both technical and computational analysis; the ability to
manage and deploy the massive information sets arising from
genomics, the availability of clinical interventions which can
be informed by such genomic analysis. NGS technology
will be a valuable tool to compliment traditional sequencing
techniques in exploring the possible new biomarkers.
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